Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University of Lorraine | OTHER |
Not provided
Not provided
Not provided
Not provided
This is a single-center cohort study aimed to describe the urinary excretion kinetics of gadolinium contrast agents (Gd-CAs). Patients with a prescription for injected MRI are invited to participate in the study. If they agree, blood and urine samples are collected before Gd-CAs injection, and urine samples are collected between 0- and two-and-a-half-hours post-injection of Gd-CAs.
The contrast agents used in MRI to characterize certain lesions contain a chemical element from the rare earth family: Gadolinium (Gd). Gd, in its isolated form, is toxic in humans, but it can still be used in the form of complex molecules such as gadolinium contrast agents (Gd-CAs), which retain its contrast power while greatly minimizing its toxicity.
The MRI is performed rapidly after the injection of Gd-CAs, and these compounds are eliminated by the urinary route in the first urine following the examination. After elimination, and in view of their very high stability, these compounds follow the path of wastewater via sewage treatment plants. However, the processes currently used in these plants do not retain them, and they remain present in the purified water discharged into rivers.
Work carried out at the Laboratoire Interdisciplinaire des Environnements Continentaux (LIEC) at the University of Lorraine has demonstrated the bioaccumulation of these compounds in freshwater organisms. Gd-CAs then follow the classic pathway of continental waters. It should be noted that the quantity of Gd released as a result of MRI activities has been estimated on average at 1 injection per 1 g of Gd used.
In order to prevent future environmental disorders, recovery of all or part of the Gd-CAs immediately after MRI by urine collection is undoubtedly the most effective approach.
The aim of this project is to assess the feasibility of such an approach, and to propose a protocol applicable to MRI involving the injection of gadolinium contrast agents for urine collection.
This project is part of the "Rare Earths" theme of LabEx R21. It will examine the possibility of recycling gadolinium as an element or as Gd-CAs.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| excretion kinetics of gadolinium contrast agents in patients | Experimental | urine samples are collected before Gd-CAs injection, and between 0- and two-and-a-half-hour post-injection of Gd-CAs. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| biological samples collection | Other | Urine samples are collected before Gd-CAs injection, and between 0- and two-and-a-half-hour post-injection of Gd-CAs. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Urinary excretion of gadolinium-based contrast agents (Gd-CAs) | Describe the kinetics of urinary excretion of GdCAs during the 2H30 following gadoline contrast injection in patients undergoing injected MRI at the Mercy Hospital Medical Imaging Department. The cumulative quantity of gadolinium-based contrast agents (Gd-CAs) (mg) mesured in urine during spontaneous micturition between 0 and 2H30 after injection of gadoline contrast medium and during micturition on demand at 2.30 h. The amount of Gd present in the urine (directly associated with the presence of Gd-CAs) is determined by inductively coupled plasma mass spectrometry (ICPMS). Urine concentrations are expressed in µg/L. Taking into account the volume of urine collected, the quantity of Gd is calculated and expressed in mg. This quantity is then expressed as a percentage of the quantity of injected-Gd-CAs. | at 2 hours and a half after Gd-CAs injection |
| Measure | Description | Time Frame |
|---|---|---|
| Renal function | Glomerular filtration rate (GFR: mL/min) estimated by the CKD-EPI method on the day of MRI. | Day 0 (MRI) |
| Volume of beverages | Volume of beverages drunk (mL) after each micturition, declared by the patient since Gd-CAs injection, to the nearest 100 mL. |
Not provided
Inclusion Criteria:
Patients:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Arpiné EL NAR, PhD | Contact | 0033387557766 | projet-recherche-clinique@chr-metz-thionville.fr | |
| Mélanie JUNKE | Contact | projet-recherche-clinique@chr-metz-thionville.fr |
| Name | Affiliation | Role |
|---|---|---|
| Rémi DUPRES, MD | CHR Metz Thionville Hopital Mercy | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHR Metz-Thionville/Hopital de Mercy | Recruiting | Metz | Grand Est | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A single-center cohort descriptive study
Not provided
Not provided
Not provided
Not provided
| at 2 hours and a half after Gd-CAs injection |
| Time to first spontaneous micturition | Duration (in minutes) between time of Gd-CAs injection and time of first spontaneous micturition. | up to 2 hours and a half after Gd-CAs injection |
| Study refusal rate | Percentage (%) of study refusal | Day 0 (MRI) |
| Rate of premature study exit | Percentage (%) of premature study exit | at 2 hours and a half after Gd-CAs injection |
| CHR Metz-Thionville / Hopital Bel Air | Not yet recruiting | Thionville | France |
|